CN101357219B - Medicine for treating chronic hepatitis B - Google Patents
Medicine for treating chronic hepatitis B Download PDFInfo
- Publication number
- CN101357219B CN101357219B CN2008101508970A CN200810150897A CN101357219B CN 101357219 B CN101357219 B CN 101357219B CN 2008101508970 A CN2008101508970 A CN 2008101508970A CN 200810150897 A CN200810150897 A CN 200810150897A CN 101357219 B CN101357219 B CN 101357219B
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- liver
- medicine
- ball
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 95
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 47
- 208000000419 Chronic Hepatitis B Diseases 0.000 title claims abstract description 23
- 229940079593 drug Drugs 0.000 title claims description 34
- 238000011282 treatment Methods 0.000 claims abstract description 53
- 241000218176 Corydalis Species 0.000 claims abstract description 26
- 239000009636 Huang Qi Substances 0.000 claims abstract description 26
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 81
- 239000000052 vinegar Substances 0.000 claims description 27
- 235000021419 vinegar Nutrition 0.000 claims description 27
- 241000756943 Codonopsis Species 0.000 claims description 25
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 25
- 235000012907 honey Nutrition 0.000 claims description 24
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 18
- 210000000582 semen Anatomy 0.000 claims description 18
- 230000033228 biological regulation Effects 0.000 claims description 12
- 239000006187 pill Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 69
- 239000008280 blood Substances 0.000 abstract description 46
- 210000004369 blood Anatomy 0.000 abstract description 45
- 210000004185 liver Anatomy 0.000 abstract description 43
- 210000000952 spleen Anatomy 0.000 abstract description 21
- 230000001737 promoting effect Effects 0.000 abstract description 13
- 208000004880 Polyuria Diseases 0.000 abstract description 6
- 230000035619 diuresis Effects 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 238000007796 conventional method Methods 0.000 abstract description 2
- 244000141331 Amomum villosum Species 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000271309 Aquilaria crassna Species 0.000 abstract 1
- 244000080767 Areca catechu Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 244000150195 Cyperus longus Species 0.000 abstract 1
- 235000018109 Cyperus longus Nutrition 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 235000005010 Scirpus paludosus Nutrition 0.000 abstract 1
- 241000329195 Sparganium erectum Species 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 235000013305 food Nutrition 0.000 description 89
- 241000699670 Mus sp. Species 0.000 description 36
- 238000012360 testing method Methods 0.000 description 27
- 241000700159 Rattus Species 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 210000003494 hepatocyte Anatomy 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 210000000941 bile Anatomy 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 230000002440 hepatic effect Effects 0.000 description 14
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 14
- 206010008909 Chronic Hepatitis Diseases 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 12
- 208000019423 liver disease Diseases 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 231100000753 hepatic injury Toxicity 0.000 description 11
- 208000006454 hepatitis Diseases 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 241000700721 Hepatitis B virus Species 0.000 description 9
- 206010023126 Jaundice Diseases 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 208000019425 cirrhosis of liver Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 239000000341 volatile oil Substances 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 8
- 208000031975 Yang Deficiency Diseases 0.000 description 8
- 208000031971 Yin Deficiency Diseases 0.000 description 8
- 230000007850 degeneration Effects 0.000 description 8
- -1 electuary Substances 0.000 description 8
- 210000000232 gallbladder Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000017074 necrotic cell death Effects 0.000 description 8
- 229960002275 pentobarbital sodium Drugs 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 101710142246 External core antigen Proteins 0.000 description 7
- 206010019755 Hepatitis chronic active Diseases 0.000 description 7
- 206010019799 Hepatitis viral Diseases 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 231100001252 long-term toxicity Toxicity 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229940117953 phenylisothiocyanate Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 201000001862 viral hepatitis Diseases 0.000 description 7
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 6
- 208000005374 Poisoning Diseases 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 231100000572 poisoning Toxicity 0.000 description 6
- 230000000607 poisoning effect Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 5
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical group C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 210000000748 cardiovascular system Anatomy 0.000 description 4
- 210000002249 digestive system Anatomy 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010052989 Naphthol AS D Esterase Proteins 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000001427 coherent effect Effects 0.000 description 3
- 210000003060 endolymph Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 206010019847 hepatosplenomegaly Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000005470 impregnation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000007449 liver function test Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- DNJFTXKSFAMXQF-UHFFFAOYSA-N Arecaidine Chemical compound CN1CCC=C(C(O)=O)C1 DNJFTXKSFAMXQF-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- ZVMJXSJCBLRAPD-ZFWWWQNUSA-N Curzerenone Chemical compound C1[C@@](C=C)(C)[C@@H](C(=C)C)C(=O)C2=C1OC=C2C ZVMJXSJCBLRAPD-ZFWWWQNUSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- ZVMJXSJCBLRAPD-UHFFFAOYSA-N Epicurzerenone Natural products C1C(C=C)(C)C(C(=C)C)C(=O)C2=C1OC=C2C ZVMJXSJCBLRAPD-UHFFFAOYSA-N 0.000 description 2
- 238000006424 Flood reaction Methods 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000035603 choleresis Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 2
- QUQIBYMETMROHZ-UHFFFAOYSA-N curzerenone Natural products CCC1(C)Cc2occ(C)c2C(=O)C1C(C)C QUQIBYMETMROHZ-UHFFFAOYSA-N 0.000 description 2
- KUFXJZXMWHNCEH-UHFFFAOYSA-N cyperone Natural products C1CC(=O)C(C)=C2CC(C(=C)C)CCC21C KUFXJZXMWHNCEH-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- DYPLDWLIOGXSSE-UHFFFAOYSA-N guvacoline Chemical compound COC(=O)C1=CCCNC1 DYPLDWLIOGXSSE-UHFFFAOYSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 229940000351 hemocyte Drugs 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- KUFXJZXMWHNCEH-DOMZBBRYSA-N (4as,7r)-1,4a-dimethyl-7-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one Chemical compound C1CC(=O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C KUFXJZXMWHNCEH-DOMZBBRYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical group C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 241000134884 Ericales Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 1
- 101710099339 Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- DTGKSKDOIYIVQL-MRTMQBJTSA-N Isoborneol Natural products C1C[C@@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-MRTMQBJTSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical group C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- NAHTXVIXCMUDLF-DUJPAFNYSA-N Toosendanin Natural products O=C(O[C@H]1C(=O)[C@H]2[C@@](C)([C@H](O)C[C@H]3[C@@]4(C)[C@H](O)OC[C@@]23[C@@H](O)C[C@H]4OC(=O)C)[C@@]23[C@]1(C)[C@H](c1cocc1)C[C@H]2O3)C NAHTXVIXCMUDLF-DUJPAFNYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical group 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- HVHKMUMXERBUAN-IFADSCNNSA-N mesobilirubin IXalpha Chemical compound N1C(=O)C(CC)=C(C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C)C(=O)N\3)CC)N2)CCC(O)=O)N1 HVHKMUMXERBUAN-IFADSCNNSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003118 prednisones Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical compound CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 description 1
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004514 sphincter of oddi Anatomy 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical group 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 150000003507 terpinene derivatives Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 238000009590 thymol turbidity test Methods 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- NAHTXVIXCMUDLF-RFNFAWMESA-N toosendanin Chemical compound C=1([C@H]2[C@]3(C)[C@@H](OC(C)=O)C(=O)[C@H]4[C@@]([C@@]53O[C@@H]5C2)(C)[C@H](O)C[C@H]2[C@@]3(C)[C@H](O)OC[C@]24[C@@H](O)C[C@H]3OC(=O)C)C=COC=1 NAHTXVIXCMUDLF-RFNFAWMESA-N 0.000 description 1
- 239000008488 toosendanin Substances 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical group 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a medicine for treating chronic hepatitis B, which contains the raw materials by the mixture ratio: 6-18% of herba artemisiae capillaries, 1-7% of Chinese thorowax, 1-7% of angelica, 3-12% of radix paeoniae alba, 3-12% of salvia miltiorrhiza, 1-10% of radix curcumae, 1-7% of rhizoma corydalis, 1-7% of common burreed rhizome, 1-7% of rhizoma zedoariae, 1-7% of nutgrass galingale rhizome, 1-7% of fructus meliae toosendan, 1-10% of dangshen, 1-7% of largehead atractylodes rhizome, 6-18% of radix astragali, 3-12% of indian bread, 1-7% of immature bitter orange, 1-7% of amomum villosum, 1-7% of areca, 0.5-5% of Chinese eaglewood and 1-7% of liquorice; the medicine is prepared by adopting conventional method. The medicine has the efficacies of clearing heat and promoting diuresis, nourishing the liver and invigorating the spleen, regulating the flow of qi and removing blood stasis, and can be used for treating chronic hepatitis B with remarkable effects, short period of treatment and rapid effects.
Description
Technical field the invention belongs to a kind of Chinese medicine preparation, is specifically related to a kind of medicine that is used for the treatment of chronic hepatitis B.
(Chronic Viral Hepatitis B CH-B) is a kind of commonly encountered diseases of serious harm human health to the background technology chronic viral hepatitis B, and its control has become a global public health problem, causes the concern of countries in the world.China is the district occurred frequently of viral hepatitis, and the average year sickness rate is 120-140/10 ten thousand.Be outstanding with hepatitis B (HB) especially wherein.China's hepatitis B virus (HBV) infection rate is up to 57.63%, and promptly the whole nation has at least 600,000,000 people to infect HBV.HBsAg positive rate 9.75% has 1.2 hundred million people approximately, accounts for 1/3 of the whole world; Wherein about 1/4 will develop into chronic hepatopathy, and part patient can develop into liver cirrhosis, even develop into hepatocarcinoma.Existing disease chronic viral hepatitis B patient more than 2,000 ten thousand people are arranged at present.There are every year 23.7 ten thousand people to die from the relevant disease of hepatitis B, wherein have 15.6 ten thousand people to die from hepatocarcinoma.Hepatitis B is serious harm China people's health not only, but also bring serious social economic burden for country.The treatment time of chronic viral hepatitis B is long, and medical expense is higher, adds Drug abuse, has more increased the weight of extra financial burden.
The chronic hepatitis B pathogeny is complicated, and many contradiction is compiled all over the body.Existing with hepatitis B continue have organism immune dysfunction again; Existing hepatocellular inflammation, necrosis have the liver proliferation of fibrous tissue again; Accumulate in the existing pyretic toxicity, obstruction of collaterals by blood stasis, deficiency of qi and yin are arranged again; The pathological changes of existing liver own also has the liver external system to change.Therefore for each chronic hepatitis B patient except that common feature is arranged, its personal characteristics is more arranged.Still do not have under the situation of sure specific medicament in treatment at present, the doctor need be on overall understanding state of an illness basis, as far as possible according to the different phase of its course of disease and the state of an illness and patient's individual characteristic, dialectical disposal, rational use of drug.
Aspect treatment, the Therapeutic Principle for chronic viral hepatitis B regulates organism immune response at present, suppresses virus replication, also answers necrosis---inflammation fibrosis simultaneously, stops to carrying out the hepatopathy development.A series of anti-HBV medicines, end is got up, and nothing more than two mechanism: (1) removes infected hepatocellular HBV by regulating immunoreation; (2) directly suppress virus replication, the healthy liver that prevents infections cell.Remove interferon-ALPHA, thymosin and new nucleoside analogues beyond the region of objective existence at present, the antivirus action of most drug is not confirmed.Interferon is a line medicine of the treatment chronic viral hepatitis B of generally acknowledging, but costs an arm and a leg, and response rate is low, and side effect is big; Though rummy husband fourth is considered to treat at present the most promising medicine of chronic hepatitis B, easily recurrence after the drug withdrawal, and can cause the hepatitis B virus sudden change, produce drug resistance.And regulating immunity of organisms and preventing that selectable medicine is few aspect the hepatic fibrosis, and side effect is bigger, and uncertain therapeutic efficacy is cut.Modern medicine has all been done more deep research to aspects such as the pathogen of chronic hepatitis B, epidemiology, natural history, pathogenesis, pathological changes, but still fails to find the hepatitis b virus infected medicine of thorough treatment.
The treatment by Chinese herbs hepatitis B has shown its advantage in every respect, because herbal species is many, classical prescription, proved recipe are many, treats the screening of hepatitis B medicine by a large amount of work, therefrom finds hepatitis B real effectively medicine and active component.Closely during the last ten years, effort by China medicine worker, the external work that Chinese medicine has been carried out antiviral, fallen enzyme, improves aspects such as immunologic function, hepatoprotective and active ingredient control in vivo,, obtained achievement preferably, produced and a collection ofly comprise that injection, oral liquid, electuary, capsule, decoction, tablet and the anti-agent of external etc. are to preparations such as the effective compound recipe of hepatitis B, folk prescription, active ingredients.At present, the medicine category of commercially available treatment hepatopathy is numerous and complicated, and effect is different, but with respect to hepatopathy mechanism complexity, most medicines seem and attend to one thing and lose sight of another that curative effect is not ideal enough.
Summary of the invention the purpose of this invention is to provide a kind of medicine that is used for the treatment of chronic hepatitis B that the treatment chronic hepatitis B is had significant curative effect.
For achieving the above object, drug component of the present invention and consumption draw by groping in a large number to sum up, and each component weight percent content is: Herba Artemisiae Scopariae 6~18%, Radix Bupleuri 1~7%, Radix Angelicae Sinensis 1~7%, the Radix Paeoniae Alba 3~12%, Radix Salviae Miltiorrhizae 3~12%, Radix Curcumae 1~10%, Rhizoma Corydalis 1~7%, rhizoma sparganic 1~7%, Rhizoma Curcumae 1~7%, Rhizoma Cyperi 1~7%, Fructus Toosendan 1~7%, Radix Codonopsis 1~10%, the Rhizoma Atractylodis Macrocephalae 1~7%, the Radix Astragali 6~18%, Poria 3~12%, Fructus Aurantii Immaturus 1~7%, Fructus Amomi 1~7%, Semen Arecae 1~7%, Lignum Aquilariae Resinatum 0.5~5%, Radix Glycyrrhizae 1~7%.
The preferred weight percent content of drug component of the present invention is: Herba Artemisiae Scopariae 11.36%, Radix Bupleuri 3.41%, Radix Angelicae Sinensis 3.41%, the Radix Paeoniae Alba 7.58%, Radix Salviae Miltiorrhizae 7.58%, Radix Curcumae 5.68%, Rhizoma Corydalis 3.41%, rhizoma sparganic 3.41%, Rhizoma Curcumae 3.41%, Rhizoma Cyperi 3.41%, Fructus Toosendan 3.41%, Radix Codonopsis 5.68%, the Rhizoma Atractylodis Macrocephalae 3.41%, the Radix Astragali 11.36%, Poria 7.58%, Fructus Aurantii Immaturus 3.41%, Fructus Amomi 3.41%, Semen Arecae 3.41%, Lignum Aquilariae Resinatum 2.27%, Radix Glycyrrhizae 3.41%.
Wherein: described Radix Bupleuri, Rhizoma Corydalis, Rhizoma Curcumae, Rhizoma Cyperi carry out processed according to the vinegar system method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one); Rhizoma sparganic carries out processed according to the concocting method that this kind item of Chinese Pharmacopoeia (2005 editions an one) is stipulated down; The Radix Paeoniae Alba, Fructus Toosendan carry out processed according to the concocting method that this kind item of Chinese Pharmacopoeia (2005 editions an one) is stipulated down; The Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus carry out processed according to the parched with bran method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one); Radix Codonopsis, the Radix Astragali, Radix Glycyrrhizae carry out processed according to the processed with honey method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one).
Medicine of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared from.Medicine of the present invention is a said dosage form on any pharmaceutics, is generally oral preparations, for example: tablet, capsule, granule, drop pill, soft capsule, enteric coated preparation, targeting preparation, slow releasing preparation etc.
Medicament selection Radix Bupleuri of the present invention, Rhizoma Cyperi, Fructus Toosendan, Fructus Aurantii Immaturus, Lignum Aquilariae Resinatum, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, Radix Curcumae, Rhizoma Corydalis, rhizoma sparganic, Rhizoma Curcumae, Semen Arecae, Fructus Amomi, Herba Artemisiae Scopariae, Poria, Radix Codonopsis, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae make up, make each efficacy of drugs produce synergism, thereby can effectively treat hepatopathy.Reach irritability with the Radix Bupleuri bar in the side; With liver-smoothing, qi-regulating, regulating functional activities of qi such as Rhizoma Cyperi, Fructus Toosendan, Fructus Aurantii Immaturus, Lignum Aquilariae Resinatum; With nourishing blood and dissolving stasises such as Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, Radix Curcumae, Rhizoma Corydalis; Amass with removing blood stasiss such as rhizoma sparganic, Rhizoma Curcumae, mill eliminating mass.Aspect blood circulation promoting and blood stasis dispelling the weight drug combination, with the effect of enhancingization disease removing food stagnancy.Again with dyspepsia and intestinal stasis relieving such as Semen Arecae, Fructus Amomis.Clearing liver-gallbladder such as Herba Artemisiae Scopariae, Poria.A little less than the existing strong spleen of liver of hepatopathy multilist, deficiency of both QI and blood is so we are again with spleen invigorating, QI invigorating, hemopoietics such as Radix Codonopsis, the Radix Astragali, the Rhizoma Atractylodis Macrocephalaes.Wherein: the main component of Radix Bupleuri is volatile oil, saponin etc., and the water logging agent of Radix Bupleuri and decoct (1:20) all can make total bile output of dog and bile salt component increase.Bupleurum preparation has certain therapeutical effect to the hepatic insufficiency that bacillary and Different types of etiopathogenises (antityphoid vaccine, ethanol, carbon tetrachloride, mouldy rice, galactosamine etc.) cause.Zoopery liver injury due to carbon tetrachloride and penicillin mould etc. there is significant anti-damaging action; The Rhizoma Cyperi main component is a volatile oil, and as α-cyperone, different cyperone etc., its decoct can promote bile secretion, improves bile flow, and the hepatocyte function to the carbon tetrachloride hepatic injury rat has protective effect simultaneously; The main component of Fructus Toosendan is Toosendanin, violet incense ketoside etc., nervous system, cardiovascular system, digestive system all there are effect, show after the healthy human oral Fructus Toosendan decoct lax Oddi's sphincter is arranged according to ultrasound investigation, shrink gallbladder, promote the bile excretion effect; The Fructus Aurantii Immaturus main component is volatile oil, flavonoid glycoside, alkaloid etc., cardiovascular system, reproductive system is had effect, and have diuresis, antiinflammatory action; The Lignum Aquilariae Resinatum main component is volatile oil, chromone compounds and derivant, callus chemical constituent, and the central nervous system is had active and the spasmolytic effect of suppressing; The Radix Angelicae Sinensis main component is volatile oil, saccharide, aminoacid and ferulic acid, vitamin B
12, vitamin A etc., cardiovascular system, blood system, immune system, central nervous system, digestive system, respiratory system all there is effect, and have antioxidation and remove free radical effect, Antiradiation injury effect, antitumor action, anti-inflammatory, antibacterial effect etc., clinical proof: Radix Angelicae Sinensis can make patient's thymol turbidity reduce, the Radix Angelicae Sinensis meals are raised mice, the hepatic tissue endogenous is breathed and is strengthened, and the ability of oxidation glutamic acid significantly improves.Studies show that: Radix Angelicae Sinensis can prevent that to the hepatic injury of chmice acute carbon tetrachloride poisoning the white mice hepatic glycogen from reducing, and protection cell ATP enzyme, G-6-Pase etc. and active illustrate that Radix Angelicae Sinensis has irregular effect to protecting hepatocyte and recovering some function of liver; Radix Paeoniae Alba main component is peoniflorin, paeonol etc., and immune system, central nervous system, digestive system, cardiovascular system etc. are all had effect, and have antiinflammatory, anti-swash should, the effect of resisting pathogenic microbes, liver is had protective effect; The Radix Salviae Miltiorrhizae main component is Tanshinone I, tanshinone, salviol etc., tool stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, the effect of the relieving restlessness that clears away heart-fire; The Radix Curcumae main component is volatile oil (linalool, curzerenone etc.), curcumin chemical compounds etc., and immune system, urinary system, blood circulation are all had effect, has antiallergic, antioxidation, antiinflammatory, antibacterial, hepatoprotective effect; The Rhizoma Corydalis main component is an alkaloid, as corydaline, tetrahydropalmatine etc., have invigorate blood circulation, promoting the circulation of QI, analgesic effect; The rhizoma sparganic main component is a volatile oil, as Ethyl formate, capryl alcohol, phenethanol etc., has anticoagulation anti-thrombosis function etc.; The Rhizoma Curcumae main component is volatile oil γ-pinene, nopinene, terpinene, isoborneol, curzerenone etc., has anti-experimental character hepatic injury effect etc.; The Semen Arecae main chemical compositions is alkaloid (arecoline, arecaidine, guvacoline etc.), fatty oil (lauric acid, myristic acid, Palmic acid etc.), have anthelmintic, resisting pathogenic microbes, bring high blood pressure down, effect such as anticancer, the effect of digestive system shown as rush down down, strengthen the ductus choledochus contractility, quicken bile and discharge; The Fructus Amomi main component is Camphora, borneol acetate etc., has former mice thrombosis that brings out with the epinephrine intermixture of anticol and acute death effect, antiulcer action, the analgesic activity that is caused thereof, can the removing dampness appetizing, warming spleen and stopping diarrha, regulate the flow of vital energy antiabortive; The Herba Artemisiae Scopariae main component is Coumarins, chromogen ketone, flavonoid, volatilization wet goods, has function of gallbladder promoting, protects the liver, the effect of analgesic, blood fat reducing, blood pressure lowering, resisting pathogenic microbes, raising body immunity; The Poria main component is polysaccharide, triterpenes, fatty acid etc., has effects such as antitumor, diuresis, enhancing immunity, analgesia, and myocardial contraction is strengthened, and heart rate is accelerated; The Radix Codonopsis main component is sterols, sugar and glycoside, alkaloid and nitrogen containing component etc., has invigorating the spleen and replenishing QI, the effect of spleen invigorating lung benefiting; Radix Astragali main component is triterpenoid saponin, flavonoid, aminoacid etc., has invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, the effect of expelling pus and promoting granulation; Rhizoma Atractylodis Macrocephalae main component is volatile oil (atractylone, atractylol, atractyloxide etc.), acetylene compound etc.; the effect that have function of gallbladder promoting, protects the liver etc.; experimentation shows; Rhizoma Atractylodis Macrocephalae decoct is oral to have protective effect to mice because of the hepatic injury that carbon tetrachloride causes; can reduce the hepatocellular degeneration necrosis, promote the growth of liver, prevent the minimizing of liver glycogen; the recovery of short DNA (deoxyribonucleic acid) has diuresis simultaneously, strengthens effects such as body immunity, blood sugar lowering.
Medicine of the present invention has clearing away heat-damp and promoting diuresis, the liver soothing and the spleen invigorating, the effect of regulating the flow of QI to dissipate blood stasis is mainly used in the chronic hepatitis B stagnation of liver-QI with deficiency of the spleen, accumulates in warm, syndrome of qi stagnation and blood stasis, card is seen: hypochondriac pain, gastral cavity abdominal distention are vexed, detest greasy, nausea and vomiting, fatigue and weak.Therapeutic effect is remarkable, has convenient oral, short treating period, instant effect, does not see obvious toxicity, clinical safe and reliable advantage.
Below further set forth the beneficial effect of medicine of the present invention by the test example, these tests comprise that a kind of dosage form big honeyed pills of medicine of the present invention is (to call in the following text: pharmacodynamics test soothing liver-QI removing food stagnancy ball), animal acute toxicity test, long-term toxicity test for animals, clinical observation on the therapeutic effect test.
Test example one: medicine soothing liver-QI removing food stagnancy ball pharmacodynamics test of the present invention
The protective effect of 1 pair of experimental hepatic injury
1.1 test material
1.1.1 medicine: soothing liver-QI removing food stagnancy ball fine powder is concentrated into the extractum shape with 45% soak with ethanol after 72 hours in 80 ℃ of water-baths, prepare desired concn with normal saline during experiment.Phenyl isothiocyanate (APIT) is pharmaceutical factory of department of pharmacy of a The 2nd Army Medical College product, liquid state, and every ml contains 1.13g, dilutes with olive oil.
1.1.2 experimental animal: test with 18~22g Kunming kind closed colony white mice; 200~300gWistar kind rat; 2.0~2.5Kg white rabbit, the male and female dual-purpose.
1.2 test method and result
1.2.1 phenyl isothiocyanate is brought out the influence of rats'liver damage
40 of rats are divided into 4 groups at random.Normal control group and APIT group normal saline are irritated stomach, every day 1 time, continuous 6 days.Soothing liver-QI removing food stagnancy ball (low dose) group is irritated stomach respectively with soothing liver-QI removing food stagnancy ball (heavy dose) group, and soothing liver-QI removing food stagnancy ball is equivalent to crude drug in whole 5g/Kg and 10g/Kg every day 1 time, continuous 6 days.Each treated animal was all irritated stomach APIT113mg/Kg except that the normal control group in the 6th day.Put to death rat extracting blood after 48 hours, measure serum glutamic pyruvic transminase (SGPT) serum bilirubin (SB); Get liver and claim weight in wet base, 10%Formalin fixes, and does histopathologic examination.Paraffin embedding, section, HE dyeing is observed and is respectively organized the change of liver organization cytopathology, and contrasts.
With KingShi improved method SGPT, the azo agents method is measured SB.
Each organizes rat SGPT and SB measurement result, and is as shown in table 1.
Table 1 soothing liver-QI removing food stagnancy ball is to the influence of rat experiment jaundice model
*Compare P<0.001 with the normal control group
*Compare P<0.001 with the APIT group
* *Compare P<0.01 with the normal control group
The hepatic tissue cell pathologic finding shows, the normal control group, and the lobules of liver structural integrity, central vein and hepatic cords are arranged normal, and sinus hepaticus does not have the expansion blood stasis, does not have strongly fragrant gallbladder phenomenon; APIT group, granular degeneration is filled the air in the obvious swelling of hepatocyte, and part of hepatocytes has steatosis and acidophilia to become, and the sinus hepaticus pressurized is irregular, and matter has mononuclear cell and lymphocytic infiltration between lobule, change such as little vasodilation hyperemia between lobule; Soothing liver-QI removing food stagnancy ball (low dose) group, the central veins of hepatic lobules dilatation and congestion, the hepatocyte granular degeneration, the Kupffer hypertrophy, the sinus hepaticus pressurized narrows down, and does not see that fat becomes and the acidophilia becomes; Soothing liver-QI removing food stagnancy ball (heavy dose) group, the central veins of hepatic lobules dilatation and congestion, the liver rope is arranged and is recovered normal, and the slight hepatic cell granular degeneration does not see that hepatocyte fat becomes and the acidophilia becomes.
1.2.2 to CCl
4Bring out the influence of mouse liver injury
40 of mices are divided into 4 groups at random.Normal control group and CCl
4Group is irritated the stomach normal saline respectively, every day 1 time, continuous 5 days.Soothing liver-QI removing food stagnancy ball (low dose) group and soothing liver-QI removing food stagnancy ball (heavy dose) group are irritated stomach respectively, and soothing liver-QI removing food stagnancy ball is equivalent to crude drug in whole 5g/Kg and 10g/Kg, every day 1 time, continuous 5 days.All the other respectively organized mouse subcutaneous injection 0.1%CCl except that the normal control group in the 5th day
4, olive oil 10ml/Kg.Put to death mice after 24 hours and get blood,, the results are shown in Table 2 with KingShi improved method SGPT.
Table 2 soothing liver-QI removing food stagnancy ball is to CCl
4The influence of damage mice SGPT
*Compare P<0.001 with the normal control group
*With CCl
4Group is P<0.001 relatively
It is liquid-solid fixed with 10%Formalin to get liver, paraffin embedding, and section, the hepatic tissue cell pathologic finding is done in H.E. dyeing.The normal control group, the lobules of liver structural integrity, central vein is positioned at lobule central authorities, and the liver rope is radial arrangement, and sinus hepaticus does not have dilatation and congestion, and hepatocyte is no abnormal; CCl
4Group, the lobules of liver soft edge, central vein hyperemia, the liver rope is arranged and is not radial, the obvious swelling of hepatocyte, the loose abortive haul shape that is of endochylema, visible balloon sample becomes, and the acidophilia becomes and the necrosis of special mess shape.Mononuclear cell, lymphocytic infiltration are arranged in the matter between lobule; Soothing liver-QI removing food stagnancy ball (low dose) group, hepatic cords is misaligned, the central vein mild hyperaemia, obvious granular degeneration of hepatocyte and puffing, the sinus hepaticus pressurized narrows down, and the hepatocyte acidophilia becomes; Soothing liver-QI removing food stagnancy ball (heavy dose) group, leaflet structure is complete, and hepatic cords is arranged and is radial, and central vein does not have the expansion blood stasis, the slight granular degeneration of hepatocyte, sinus hepaticus is high-visible, does not see downright bad the change.
1.2.3 choleretic effect to rabbit
10 of rabbit are divided into 2 groups at random, urethane 1g/Kg intravenous anesthesia, cut the abdominal cavity open, the ligation ductus choledochus inserts polyethylene catheter and collects bile in gallbladder, collect the choleresis of 30min before the administration, every 30min writes down choleresis once after the administration, totally 4 times.The matched group rabbit is through capacity normal saline such as duodenum injection and administrations, and experimental group injects soothing liver-QI removing food stagnancy ball 5g/Kg by duodenum, calculates the bile secretion increment rate as follows.
Experimental result shows that bile flow obviously increases in the soothing liver-QI removing food stagnancy ball duodenal administration 30min, and the bile secretion increment rate is 82.2 ± 19.1% (P<0.01).The bile secretion increment rate is 65.8 ± 23.7% (P<0.05) in the administration 60min.The bile secretion increment rate is then not obvious in the 90min is 23.2 ± 21.1% (P〉0.05).
1.2.4 to CCl
4The influence of poisoning mice pentobarbital sodium length of one's sleep
30 of white mice are divided into 3 groups at random.Normal control group and CCl
4Group is irritated capacity normal saline such as stomach, and soothing liver-QI removing food stagnancy ball group is irritated stomach soothing liver-QI removing food stagnancy ball 5g/Kg, every day 1 time, continuous 5 days.The 5th day except that the normal control group, subcutaneous injection 1%CCl simultaneously
4Olive oil 10ml/Kg.The 6th day 3 groups of equal lumbar injection pentobarbital sodium of mice 30mg/Kg.Observe mice sleep induction period and recovery time, the results are shown in Table 3.
Table 3 soothing liver-QI removing food stagnancy ball is to CCl
4The influence of poisoning mice pentobarbital sodium length of one's sleep
*Compare P<0.001 with the normal control group
*Compare P with the normal control group〉0.05
CCl
4The poisoning mice pentobarbital sodium sleep derivation phase obviously shortens, recovery time significant prolongation, soothing liver-QI removing food stagnancy ball is to CCl
4No significant difference between poisoning mice pentobarbital sodium sleep derivation phase and convalescent period and the normal control group illustrates that soothing liver-QI removing food stagnancy ball has powerful protective effect to liver.
1.3 conclusion
Prepared whole animal experimental model in the research of this experimental hepatitis is the classical way commonly used that is used for studying the effect of medical treatment hepatopathy, and CCl is arranged
4Toxic liver injury model and cholestasis jaundice model etc.The former passes through CCl
4In liver, combine with cytochrome P-450, produce free radical, thereby make lipid oxidation, form the peroxide of lipid, influence the functional group on the protein, particularly the SH base is destroyed other structures of endocytoplasmic reticulum and cell, GPT in the endochylema etc. overflows in the blood, makes the active obviously rising of these enzymes in the blood.The once heavy dose of acute poisoning of phenyl isothiocyanate, can cause that blood mesobilirubin and SGPT sharply raise, bile flow reduces, and the interior bile capillary of hepatocyte injury and liver damages and causes liver internal congestion jaundice, is the new hepatic of research both at home and abroad at present and the common experimental model of function of gallbladder promoting medicine.
This research uses these two kinds of livers to decrease animal model, and the result shows, CCl
4After the chmice acute hepatic injury 24 hours, SGPT can raise rapidly, than normal level up to 13 times about, after the hepatic injury of phenyl isothiocyanate rat acute 48 hours, SGPT rose suddenly to about 7 times of normal level.Under liver function major injury situation like this, soothing liver-QI removing food stagnancy ball 5-10g/kg, medication 5-6 days, can reduce the effect of SGPT very significantly, show that this product has very strong protective effect to hepatocyte.
Behind the phenyl isothiocyanate rat oral gavage 48 hours, SB is elevated to 4.28 ± 0.23mg/dL, is higher than about 17 times of rat normal values.Proof this product has the SB rising that obvious antagonism phenyl isothiocyanate causes, experimental jaundice is had unique jaundice eliminating effect.
The experiment of rabbit bile flow also can be seen, and soothing liver-QI removing food stagnancy ball has the effect of remarkable increase bile flow, and this is consistent with the experimental result that the rat jaundice disappears.So think this product jaundice eliminating and the effect of soothing liver-QI removing food stagnancy, may be relevant with its effect that can significantly increase bile secretion.
Soothing liver-QI removing food stagnancy ball is to CCl
4The poisoning mice pentobarbital sodium length of one's sleep and normal mouse pentobarbital sodium comparison length of one's sleep no difference of science of statistics.Soothing liver-QI removing food stagnancy ball experimental group and CCl
4The poisoning treated animal is compared, and the latter prolongs the pentobarbital sodium sleep significantly.This experiment further points out soothing liver-QI removing food stagnancy ball to CCl
4Hepatic injury has good protective effect.
From pathological tissue cytolgical examination result, no matter be CCl
4Or phenyl isothiocyanate, soothing liver-QI removing food stagnancy ball treated animal liver tissue lesions is all light than matched group.Particularly the difference of hepatic necrosis degree is more remarkable.The necrosis of tangible kitchen range shape appears in matched group, and soothing liver-QI removing food stagnancy ball group then shows kitchen range shape necrotic extent and dwindles, even does not have necrosis.This result has important relation to the prognosis of hepatic injury.Think that the reticular fiber support subsided when the necrosis of kitchen range shape appearred in hepatocyte, when liver cell regeneration,, then be irregular nodular pattern, lose the 26S Proteasome Structure and Function of original lobule, can develop into liver cirrhosis for a long time owing to lost original support.
In sum, effects such as soothing liver-QI removing food stagnancy ball not only has the hepatocellular degeneration of alleviating, necrosis, the jaundice that disappears, function of gallbladder promoting, and take place also significant to the prevention liver cirrhosis.The experimental studies results of this respect is consistent with the clinical effectiveness of soothing liver-QI removing food stagnancy ball, so this medicine is comparatively ideal treatment hepatitis new drug.
2 pairs of hemorheological influences
2.1 test material
2.1.1 medicine: soothing liver-QI removing food stagnancy ball fine powder, irritating the stomach preparation is that fine powder is concentrated into the extractum shape with 45% soak with ethanol after 72 hours in 80 ℃ of water-baths, with preceding dilution desired concn.The used for intravenous injection preparation is that fine powder is concentrated into the extractum shape with the distilled water soak at room temperature after 72 hours in 80 ℃ of water-baths, the time spent press the desired concn distilled water diluting it.
2.1.2 experimental animal: 200~300gWistar kind rat; 2.0~2.5Kg rabbit, the male and female dual-purpose.
2.2 test method and result
2.2.1 whole blood contrast viscosity
Get 10 of rabbit, press the determination of ubbelohde viscometer method, measure every rabbit administration before, the capillary glass tube required time of 0.5ml whole blood in 37 ℃ of water-baths (heparin anti-coagulating 125u/ml) by 8cm, internal diameter 0.55mm.After soothing liver-QI removing food stagnancy ball 10g/kg irritates stomach 60min, pass through the time with same procedure mensuration.Measure the normal saline required time of equal volume simultaneously, ask its ratio promptly to get whole blood contrast viscosity, result such as table 4.
Table 4 soothing liver-QI removing food stagnancy ball is to the influence of rabbit blood viscosity
*P<0.001
2.2.2 plasma viscosity
Get 10 of rabbit, press the determination of ubbelohde viscometer method, measure before every rabbit administration and to behind the soothing liver-QI removing food stagnancy ball 10g/kg60min, 1ml blood plasma is by the capillary glass tube required time of long 11cm, internal diameter 0.55mm in 25 ℃ of water-baths.Measure simultaneously with volume normal saline required time, try to achieve ratio, the result is as shown in table 1.
2.2.3 erythrocyte electrophoretic time
Get 10 of rabbit, be divided into 2 groups at random.The normal control group is irritated capacity normal saline such as stomach; Experimental group is irritated stomach soothing liver-QI removing food stagnancy ball 10g/kg.60min before the administration and after the administration gets blood from arteria auricularis, and each 5ml isolates hemocyte and blood plasma, puts erythrocyte in self blood plasma and normal saline, observes and electrophoresis time, the results are shown in Table 5.
Table 5 soothing liver-QI removing food stagnancy ball is to the influence of rabbit erythrocyte electrophoretic time
*Compare with the normal control group
2.2.4 to thrombotic influence
10 of rat are divided into 2 groups at random.Normal control treated animal intravenous injection equivalent normal saline; Experimental group intravenous injection soothing liver-QI removing food stagnancy ball 10g/kg.Rat pentobarbital sodium 30mg/kg intravenous anesthesia, the circulation of qi promoting cannula, separate right common carotid artery and left external jugular vein, be full of the polyethylene tube of three sections connections with the 50u/ml heparin-saline, No. 4 surgical threads of a long 7cm are put in the pipe stage casing, and left external jugular vein and right common carotid artery are successively inserted in the pipe two ends, behind intravenously administrable or the normal saline, open immediately bulldog clamp makes blood circulation.Herba Clinopodii in behind the 15min takes out silk thread and claims wet weight of thrombus.Calculate thrombosis by following formula.
The results are shown in Table 6, soothing liver-QI removing food stagnancy ball can suppress rat suppository very significantly and form.
Table 6 soothing liver-QI removing food stagnancy ball is to the thrombotic influence of rat experiment
Group | Dosage (g/kg) | Number of animals | Wet weight of thrombus (meansigma methods ± SDmg) | Suppression ratio (%) |
Normal saline | 5 | 59.14±8.78 | ||
Soothing liver-QI removing food stagnancy ball | 10.0 | 5 | 24.40±6.83 | 58.74 |
2.3 conclusion
Originally having experimental results show that soothing liver-QI removing food stagnancy ball 10g/kg has reduces whole blood viscosity and plasma viscosity ratio significantly, shortens erythrocyte electrophoretic time and suppresses effect such as thrombosis.Thereby can strengthen the fluidity of blood in liver vessel, and improve the liver microcirculation and remove microcirculation disturbance, help the supply of hepatocellular nutrition and oxygen, this recovery to hepatopathy has great importance.Motherland's medical science is thought, hepatic region twinge, gastral cavity rib distension, be owing to depression of liver-QI, the vapour lock stasis, QI-blood circulation does not freely cause the blood stasis state, soothing liver-QI removing food stagnancy ball can play blood circulation and promoting silt, the merit of liver-smoothing, qi-regulating, and its mechanism may have substantial connection with the improvement of its hemorheological property.
Multiple factors such as macromole concentration such as cholesterol, celloglobulin are relevant in the change of whole blood viscosity and plasma viscosity and the quantity of hemocyte, quality, the blood plasma.Wherein erythrocyte cohesion ability in blood has close ties with erythrocyte surface band negative charge of the same race again, and measuring erythrocyte electrophoretic time is the important indicator of reflection erythrocyte charge number.When erythrocyte surface is with negative charge number of the same race to increase, then can strengthen negative charge repulsive interaction of the same race between erythrocyte, make erythrocyte be difficult for assembling, thereby cause blood viscosity to descend.This experiment shows that soothing liver-QI removing food stagnancy ball has the erythrocyte of shortening electrophoresis time in self blood plasma and normal saline, and prompting this product has the effect that increases erythrocyte surface negative charge quantity.
Blood viscosity is influenced by plasma viscosity also, and plasma viscosity depends primarily on the content of celloglobulin, lipid etc.Soothing liver-QI removing food stagnancy ball can make plasma viscosity reduce significantly, also must influence the decline of whole blood viscosity.Influenced which kind of protein content in the blood plasma as for soothing liver-QI removing food stagnancy ball, remained further to be studied.
3 immunological effects
3.1 test material
3.1.1 medicine: soothing liver-QI removing food stagnancy ball fine powder, press desired concn dilution 4 during experiment.Lyophile complement, Lanzhou biological produce lot number: 86004.Lysozyme, fowl egg two factories in Shanghai produce, lot number: 880120.Anti-HBs, Lanzhou biological produce lot number: 87003.
3.1.2 experimental animal: test with 18~22g Kunming kind white mice, male and female dual-purpose.
3.2 test method and result
3.2.1 the influence to organs such as Mouse Liver, spleen and thymus: soothing liver-QI removing food stagnancy ball I group is by quite primary dose 10g/kg, soothing liver-QI removing food stagnancy ball II group is by quite primary dose 5g/kg, levamisole is pressed 25mg/kg and is irritated stomach, once a day, continuous 7 days, put to death mice on the 8th day, win liver, spleen, thymus and claim weight in wet base, calculate the organ weights of per 10 gram body weight, the results are shown in Table 7.
The influence (n=7) of table 7 pair Mouse Liver, spleen and thymus
*P<0.05
**P<0.01
3.2.2 the influence to serum lysozyme: soothing liver-QI removing food stagnancy ball medication is the same, and cyclophosphamide is pressed the 15mg/kg intramuscular injection.Got blood system from serum on the 8th day, and measured serum lysozyme content, the results are shown in Table 8 with agar diffusion method.
The influence (n=12) of table 8 pair mice serum lysozyme
3.2.3 the influence to the reticuloendothelial system carbon clearance: medication is the same, the 8th day mouse vein injects the india ink 0.2ml of 1:8 dilution, the immediate record time, in second, 10,25 minute eye socket blood sampling 0.025ml, be added among the 0.1% sodium carbonate liquor 2ml, in spectrophotometer, read the 0D value, obtain carbon clearance rate K value, and use formula with the survey of 650nm wavelength
Proofread and correct, the results are shown in Table 9.
The influence (n=7) of table 9 pair mice carbon clearance
3.2.4 to the active influence of the acid nonspecific esterase of peripheral blood lymphocyte: method is the same, the 8th day mice cut tail and gets the blood push jack and do ANAE dyeing, and split under the oily mirror, 100-200 lymphocyte of tail different parts counting write down the reactor, obtain the ANAE positive rate, the results are shown in Table 10.
The influence (n=7) of table 10 pair peripheral blood lymphocyte ANAE reaction
3.2.5 the influence to body endolymph cell: medication was the same, added phytohaemagglutinin (PHA) 6mg/kg in the 2nd day, intramuscular injection, once a day, for three days on end.Test and got the blood push jack on the 5th day, Wright dyeing, split, tail different parts are observed 100 lymphocytes, and record transforms the lymphocyte number of (comprising transitional type), calculates conversion ratio, the results are shown in Table 11.
The influence (n=10) of table 11 pair body endolymph cell
3.2.6 the influence that antagonist generates: administration proxima luce (prox. luc) lumbar injection 5% Sanguis Gallus domesticus ball 0.2ml immune mouse, method is the same, continuous 6 days.Immunity was got blood system from the determination of serum hemolysin level on the 8th day, the results are shown in Table 12.
The influence (n=12) that table 12 pair hemolysin forms
3.2.7 to the inhibition of HBsAg experiment: soothing liver-QI removing food stagnancy extract of bolus (5g/ml) passed doubly dilute, drip in the plate of shallow lake and Ag at the medical blood clotting of " u " type
+Patients serum's (electrophoresis tire 1:16) effect 2 hours is carried out counter electrophoresis with anti-HBs then routinely, and for inhibitory action (+) is arranged, disappearance person is not unrestraint effect (-), the results are shown in Table 13 with precipitation line disappearance person.
Table 13 pair HBsAg inhibition test
*Shelved after the use 6 days
3.3 conclusion
This experimental result shows that soothing liver-QI removing food stagnancy ball has the mice of promotion reticuloendothelial system carbon clearance, strengthens monokaryon-macrophage activity, improves peripheral blood lymphocyte ANAE positive rate, increases the T percentage of lymphocyte, and promotes the effect that specific antibody generates.Simultaneously also can promote atrophy of thymus gland, reduce PHA and stimulate the body endolymph cell transformation that is produced, suppress the T lymphocyte activation.Liver, spleen and serum lysozyme etc. then there is not obviously influence.In vitro tests is not seen inhibitory action to HBsAg yet.
The pathology damage reason more complicated of hepatitis be it is generally acknowledged not to be by due to the hepatitis virus direct infection destruction hepatocyte, but relevant with immunoreation.Cause humoral immunization and the cellular immunization that surface of hepatocytes antigen changes at viral infection and all can damage hepatocyte, but think it mainly is, also can suffer from serious acute hepatitis in default of the patient of the r-globulinopenia of antibody by due to the specific cellular immunity.Chronic active hepatitis (CAH) patient that liver tissue injury is more serious, its cellular immunization is particularly evident, and continues to exist with course of disease development.These patients are treated with immunosuppressive drugs such as prednisones, and not only clinical symptoms, liver function index are eased and improve, and also temporarily transfer to normal to cellular immunization (comprising T cell and the K cell immune response) mensuration of liver specificity membrane antigen.Domestic also someone reports that the curative effect of the preceding application class hormonal medicaments of antiviral therapy is more than application person is not good.On the contrary, chronic persistence hepatitis B (CPH-B) patient, its humoral immunization and cellular immunization are all low to the antigenic identification activity of special surface of hepatocytes.Though having, soothing liver-QI removing food stagnancy ball directly do not suppress the HBsAg activity, but can promote monokaryon-macrophage activity, increase the specific antibody generation, improve the periphery blood T lymphocyte ratio, so help the elimination of liver plasma membrane specific antigen, stop the intercellular propagation of HBv, and the recovery of immune response immunologic function when low.Simultaneously, because the T lymphocyte activation is had inhibitory action, so can reduce cellular immunization to hepatocellular attack, the amelioration of inflammation reaction reduces hepatocyte injury.Therefore, soothing liver-QI removing food stagnancy ball may be a kind of good immunomodulator, and rational Application then helps the hepatopathy recovery from illness.
Test example two: medicine soothing liver-QI removing food stagnancy ball animal acute toxicity test of the present invention
1 test material
1.1 medicine: soothing liver-QI removing food stagnancy ball is done following extraction respectively and is handled:
1.1.1 injection for intravenous reagent: soothing liver-QI removing food stagnancy ball fine powder floods with the distilled water room temperature, each 72 hours, flood secondary altogether, and first and second time flooded with the distilled water in 5,3 times of crude drug amounts respectively.Impregnation liquid is filtered merging, and it is standby to be concentrated into 2.5g/ml (amounting to crude drug total amount meter) in 80 ℃ of water-baths, faces the time spent by the desired concn distilled water diluting.
1.1.2 supply oral reagent: soothing liver-QI removing food stagnancy ball fine powder floods 2 times with 45% analytical pure ethanol room temperature, each 72 hours, first and second time is respectively with in the alcohol dipping of 5,3 times of crude drug amounts, impregnation liquid is filtered merging, it is standby to be concentrated into 15g/ml (amounting to crude drug total amount meter) in 80 ℃ of water-baths, faces the time spent and dilutes by desired concn.
1.2 experimental animal: experiment is provided by Lanzhou Institute of Biological Products with 18~22g Kunming kind closed colony white mice.
2 test methods and result
2.1 pick out healthy 20 of the experiment mices (male and female half and half) of hindering body weight 19 ± 1g that do not have,, one by one mice carried out the tail vein injection administration with sequential method by the reagent of the intravenously administrable volume dilution sequential method requirement dosage of 0.2ml/10g body weight.The death of each experiment mice distributes with survival in the observed and recorded 5 minutes.With gained as a result the substitution formula calculate.
Experimental result shows, the LD of mouse mainline
50=25.7/kg (amounting to crude drug total amount meter) sees table 14 for details.
Purgation acute toxicity testing table as a result on the table 14 mouse mainline soothing liver-QI removing food stagnancy ball
"+" dead "-" survival
Hinder body weight 19 ± 1g experiment mice 2.2 select healthy nothing, with experiment mice fasting 12 hours (can't help water).By the body weight random packet, 10 every group, male and female half and half are divided into three groups.By mice 0.4ml/10g body weight administration volume conversion dilution reagent for oral use, give three groups of mices respectively by simplifying the probit method requirement, be subjected to the reagent thing, observe the reaction of animals situation after the administration immediately.Observed 7 days continuously, the record death toll is obtained mortality rate, and substitution three dose counting formula are asked the oral LD of this medicine mice
5095% fiducial limit.
The result shows the LD of this medicine
50The 95% credible 271.14-723.10g/kg of being limited to (amounting to medicine total amount meter) see table 15 for details.
The oral soothing liver-QI removing food stagnancy of table 15 mice ball acute toxicity testing is table as a result
Y meansigma methods=4.14 W summation=14.4
3 conclusions
The oral LD of this medicine
50Value belongs to harmless substantially scope from the acute hierarchical table of chemical substance.The possible lethal dose of human oral is greater than 1200 grams.
From oral this medicine experimental result of white mice 240/kg mortality rate is zero.Do the margin of safety inspection with this, try to achieve the mouse tolerance dose multiple and be:
Mice tolerance safety multiple=1177
(generally requiring multiple is to be safety at 100 o'clock)
Directly feed honeyed pill after two weeks for mice, administration group and natural death rate difference nonsignificance (P〉0.05).And the mice activity freely.
From The above results as seen.Clinical take safe and reliable.
Test example three: medicine soothing liver-QI removing food stagnancy ball long-term toxicity test for animals of the present invention
1 test material
1.1 medicine: soothing liver-QI removing food stagnancy ball fine powder by, with 45% medicinal alcohol normal temperature dipping 72 hours, filter.Medicinal residues are used 45% medicinal alcohol twice at normal temperatures, flood first and second time time to be respectively 48,24 hours, impregnation liquid are filtered merge, and being concentrated in 80 ℃ of water-baths does not have alcohol.During experiment, press the desired concn dilution with distilled water.
1.2 experimental animal: body weight 100 ± 20gWistar kind healthy rat in six ages in week is provided by Animal Experimental Study chamber, institute of oncology, Gansu Province.
2 test methods and result
2.1 method
With indoor feeding one week of experimental rat at 20 ± 2 ℃, the physiological and biochemical index that the determination experiment chamber is observed once.Physiological and biochemical index comprises hemogram (RBC, WBC, Nb, OC), and liver function (icteric index, zinc sulfate turbidity, SCPT), kidney merit (blood urea nitrogen) are selected 80 of the normal animals of every index.Be divided into 4 groups by the body weight stratified random, 20 every group, male and female half and half are divided four groups of high, medium and low, blanks.The high dose group dosage is 33g/kg/d (being equivalent to 100 times of clinical human crude drug in whole dosage), middle dosage group is 16.5g/kg/d (being equivalent to 50 times of clinical human crude drug in whole dosage), low dose group is 8.25g/kg/d (being equivalent to 25 times of clinical human crude drug in whole dosage), the blank group gives to irritate stomach equal volume normal saline with the administration group, once a day, continuous 90 days, sacrificed by exsanguination after the drug withdrawal, get blood and make the hemogram biochemical indicator, corpse is done the pathology inspection.
Other observation index: general behavior activity, body weight, feces etc.Per 10 days of body weight claims once, in time adjusts dosage, and the organ that pathological anatomy is checked is had the inclination, liver, spleen lung, kidney, thymus, stomach, adrenal gland, carries out overview, draws materials, fixes, cuts into slices, dyes and do microscopic examination.
2.2 result
2.2.1 general situation
Rat vegetative activity between each administration group and the normal saline blank group is all normal, and hair color is glossy and be close to body, and feces is normal, does not have unusual sign such as diarrhoea, loose stool.Dynamic observing of body weight shows no significant difference between four groups.See table 16 for details.
The oral rat long term toxicity of table 16 soothing liver-QI removing food stagnancy ball body weight change table
2.2.2 blood and biochemical indicator are observed:
Between each administration group and the normal saline blank group, the rat hemogram is before liver function (SCPT, ZnTT, II), renal function (UN) administration, during the administration 45 days, administration was after 90 days, every index, all belong to normal range, mathematical statistics, also no significant difference between each group.Above-mentioned leading indicator sees Table 17, table 18.
The oral rat long term toxicity of table 17 soothing liver-QI removing food stagnancy ball hemogram change list (meansigma methods ± SD)
The oral rat long term toxicity of table 18 soothing liver-QI removing food stagnancy ball changes of biochemical indexes table (meansigma methods ± SD)
2.2.3 pathologic finding
The relative weight of each important organ of the oral soothing liver-QI removing food stagnancy of rat ball is learned processing by statistics, proves no significant difference between four groups.See table 19 for details.
Table 19 soothing liver-QI removing food stagnancy ball long term toxicity test pathology test result (meansigma methods ± SD)
3 conclusions
This experiment is according to Ministry of Health of the People's Republic of China's " provisions for new drugs approval " " about the supplementary provisions and the explanation of Chinese medicine problem " and the evaluating suggestion of Ministry of Public Health committee of drug evaluation and research design.
Body weight, feces and general behavior activity that the oral soothing liver-QI removing food stagnancy of rat ball long term toxicity test is observed; Many indexs such as hemogram, hepatic and renal function and pathologic finding each vitals, especially thymus there is no evident difference between administration group and matched group.Dosage is up to 100 times of clinical consumptions, and continuous 90 days, all do not demonstrate the drug toxicity reaction symptom, can think that soothing liver-QI removing food stagnancy ball reality is nontoxic.
Test example four: medicine soothing liver-QI removing food stagnancy ball clinical observation on the therapeutic effect test of the present invention
1 clinical data
1.1 physical data
403 routine patients all are diagnosed as chronic hepatitis B through clinical, lab testing, have got rid of chronic diseases such as the heart, lung, kidney.403 routine patients are divided into two groups according to randomization, and 303 examples are organized in treatment, matched group 100 examples.Wherein male 293 examples, women 110 examples; The oldest person 72 years old, reckling 4 years old, 34 years old mean age; The elder of the course of disease 22 years, the shortest person half a year, average course of disease 11.25.Situations such as the age-sex of two groups of cases, the state of an illness and the course of disease have comparability.
Wherein treatment group is 303 examples.Matched group is 100 examples.Be 15 months observing time.
1.2 traditional Chinese medical science typing and Western medicine diagnose
Traditional Chinese medical science typing: according to " the clinical research guideline of treatment by Chinese herbs viral hepatitis " promulgated by the ministries or commissions of the Central Government, the Chinese medical discrimination typing in " viral hepatitis is prevented and treated scheme " is worked out in infectious disease academic meeting in the whole nation, Zhengzhou in November nineteen eighty-three, primary disease is divided into six types, damp and hot type 72 examples of not using up of wherein treatment group, liver-depression and spleen-insufficiency type 114 examples, liver-kidney yin deficiency 29 examples, yang deficiency of spleen and stomache 11 examples, type of deficiency of both QI and YIN 40 examples, qi stagnation and blood stasis type 37 examples, damp and hot type 21 examples, liver-depression and spleen-insufficiency type 47 examples do not use up of matched group, liver-kidney yin deficiency 11 examples, yang deficiency of spleen and stomache 4 examples, type of deficiency of both QI and YIN 5 examples, qi stagnation and blood stasis type 12 examples.
Western medicine diagnose: work out " viral hepatitis is prevented and treated scheme " as diagnosis basis according to " the clinical research guideline of treatment by Chinese herbs viral hepatitis " promulgated by the ministries or commissions of the Central Government, the academic meeting of the whole nation, Zhengzhou in November nineteen eighty-three infectious disease.Wherein treatment group chronic persistent hepatitis 157 examples, chronic active hepatitis 71 examples, liver cirrhosis due to hbv 43 examples, hepatitis B virus carriers 32 examples.Matched group chronic persistent hepatitis 59 examples, chronic active hepatitis 30 examples, liver cirrhosis due to hbv 11 examples.
1.3 Therapeutic Method
1.3.1 grouping and Therapeutic Method
403 examples are divided into treatment group and matched group at random.The treatment group is taken soothing liver-QI removing food stagnancy ball, and three times on the one, each 1-2 ball, warm water delivery service after meal, matched group is taken " academic conference of national viral hepatitis special topic " and is recommended effective medicine ease pill, and usage is the same, takes double-blind method.Two groups all with around be a course of treatment.Serve on three courses of treatment, carry out the inspection of every lab index after per course of treatment, and the record symptom, the variation of sign in addition, is carried out treatment in long term (half a year) after finishing soothing liver-QI removing food stagnancy ball course of treatment and is followed up a case by regular visits to (8 months) observation taking 53 routine chronic hepatitis B patients.
The period in a medicine diet is greasy, raw and cold, maror, absolute alleviating alcohol addiction.
1.3.2 MAIN OUTCOME MEASURES:
Symptom, sign, doctor trained in Western medicine inspection (liver function test: thymol turbidity test, glutamate pyruvate transaminase; Serum albumin; The liver ultrasound investigation, the hepatitis b virus marker inspection).
1.4 curative effect is judged:
According to the academic meeting of " the clinical research guideline of treatment by Chinese herbs viral hepatitis " promulgated by the ministries or commissions of the Central Government, the November nineteen eighty-three whole nation, Zhengzhou infectious disease, and with reference to the internal medicine hepatopathy meeting of the whole nation, Tianjin in 1991, in conjunction with the side of offering people clinical experience and ordering for many years.
1.4.1 clinical basic healing:
1, clinical card marquis disappears;
2, hepatosplenomegaly is stablized no change or retraction, and the hepatic region does not have the pain of tunking;
3, liver function test recovers normal;
4, the hepatitis B person requires HBV-N to duplicate the cloudy commentaries on classics of index, and HBsAg can be positive;
5, above every stable 6-12 month person.
1.4.2 produce effects:
1, clinical symptom disappearance is more than half or take a turn for the better and to account for more than 2/3;
2, the stable or retraction of hepatosplenomegaly, the hepatic region does not have tenderness or kowtows pain;
3, the normal or slight abnormality of liver function recovery;
4, hepatitis B requires HBV-N to duplicate index cloudy a commentaries on classics, but HBsAg still can be positive.
1.4.3 effectively:
1, clinical symptom disappearance is more than 1/3 or take a turn for the better and to account for more than 1/2;
2, hepatosplenomegaly is stablized constant or retraction, and the hepatic region does not have percussion pain;
3, the more former inspection value of liver function test descends more than 1/2;
4, hepatitis B requires HBV-N to duplicate index to descend to some extent, but HBsAg still can be positive.
1.4.4 it is invalid: as not reach These parameters person.
2 results
2.1 two groups of Chinese medical discrimination typing efficacy results see table 20 for details.
Table 20 Chinese medical discrimination typing efficacy analysis table
The clinical cure rate of treatment group as can be seen from the table is 30.03%, and produce effects 36.63% takes a turn for the better 26.07%, and total effective rate is 92.74%; And the matched group clinical cure rate is 6%, and produce effects 20% takes a turn for the better 24%, and is invalid 50%, total effective rate be 50%, two group of curative effect relatively, learn by statistics and handle difference highly significant meaning (P=0.001) is arranged.Liver-depression and spleen-insufficiency type between two groups again, liver-kidney yin deficiency has significance meaning (preceding amphitypy P value is 0.025<P<0.05, and type of deficiency of both QI and YIN is 0.005<P<0.01) between type of deficiency of both QI and YIN difference.
The treatment group is learned processing by statistics, find damp and hot to the greatest extent between type and liver-kidney yin deficiency, yang deficiency of spleen and stomache, type of deficiency of both QI and YIN, the qi stagnation and blood stasis type difference significance meaning (the P value is respectively 0.002<P<0.005, P<0.001,0.001<P<0.002, P<0.001) is all arranged; Liver-depression and spleen-insufficiency type and liver-kidney yin deficiency, yang deficiency of spleen and stomache, type of deficiency of both QI and YIN, qi stagnation and blood stasis type differences also have highly significant (the P value is P<0.001); Liver-kidney yin deficiency and yang deficiency of spleen and stomache differences have highly significant meaning (P<0.001); Yang deficiency of spleen and stomache and type of deficiency of both QI and YIN, qi stagnation and blood stasis type differences have highly significant meaning (the P value is P<0.001); Equal zero difference between surplus each group.To the greatest extent type and liver-depression and spleen-insufficiency type curative effect are not better to damp and hot for treatment group as seen from the table, and type of deficiency of both QI and YIN and qi stagnation and blood stasis type take second place, and liver-kidney yin deficiency and yang deficiency of spleen and stomache more take second place.
2.2 two groups of Western medicine diagnose efficacy analysis see table 21 for details.
Table 21 liang group Western medicine diagnose efficacy analysis
As can be seen from the table, two groups cure rate, obvious effective rate, effective percentage, inefficiency and total effective rate are with traditional Chinese medical science typing efficacy analysis.The chronic persistent hepatitis of treatment group and matched group, chronic active hepatitis, liver cirrhosis due to hbv differences have highly significant meaning (the P value is P<0.001).
In the treatment group again, learn to handle by statistics, find that then soothing liver-QI removing food stagnancy ball is better to chronic persistent hepatitis,, to virus carrier, chronic active hepatitis and liver cirrhosis due to hbv (chronic persistent hepatitis and chronic active hepatitis: 0.002<P<0.005 of then taking second place; Chronic persistent hepatitis and liver cirrhosis due to hbv P<0.001, equal zero difference between all the other each groups).
2.3 two groups of variations for the treatment of front and back symptom, sign; See table 22 for details.
The variation of symptom, sign before and after the treatment of table 22 group
As can be seen from the table, soothing liver-QI removing food stagnancy ball also has better action to improving clinical symptoms and sign, such as hypochondriac pain, the side of body down long-pending piece, gastral cavity abdomen go up painful etc. and all the significance meaning to be arranged with matched group difference, see for details in the table.
2.4 two groups of variations that treatment back Western medicine diagnose is checked see table 23 for details.
The variation of table 23 liang group treatment back laboratory examination
*P<0.001
From showing as can be known soothing liver-QI removing food stagnancy ball to improving the turbid test of Moschus moschiferous, glutamate pyruvate transaminase, A/G is inverted all better action, and learning by statistics to handle all has significant difference (the P value is P<0.001) with matched group.
2.5 after two groups of treatments, HBV-N conversion situation relatively; See table 24 for details.
Table 24 a liang group treatment back HBV-N transforms situation
Grouping | HBsAg | Anti--HBs | HBeAg | Anti--HBe | Anti--HBc |
The treatment group | 41/263 | 17/234 | 37/82 | 36/85 | 13/242 |
Matched group | 6/100 | 4/100 | 5/78 | 5/80 | 5/91 |
Treatment group HBsAg, HBeAg, anti--HBe conversion ratio all are higher than matched group (P<0.001), and do not have statistical significance between anti--HBs, anti--two groups of HBc.Illustrate that soothing liver-QI removing food stagnancy ball all has better action to the conversion of HBsAg, HBeAg, anti--HBe.
2.6 two groups of different course are to the comparison of chronic viral hepatitis B curative effect:
Two groups of different course find that relatively treatment group and matched group difference all have significance meaning (P<0.001), see table 25 for details.
Table 25 liang group different course is to the overall merit of chronic hepatitis B curative effect
*P<0.001
2.7 situation is followed up a case by regular visits in treatment at a specified future date:
We are from the chronic hepatitis B patients that hospital accepts for medical treatment, 53 routine patients are continued to treat 3 courses of treatment, the result cures 40 examples, produce effects 9 examples, effective 4 examples, total effective rate is 100%, treatment was followed up a case by regular visits to 8 months after finishing, 53 routine patient symptoms disappear as a result, and it is normal stable that hepatopathy is recovered fully, and HBVN also has improvement to a certain degree; Wherein the moon changes 1 example in HBsAg8 month, and negative conversion rate is 2.7%; Anti-HBs does not have 1 example changes sun; Cloudy 3 examples of changeing of HBeAg, negative conversion rate is 27.27%, and anti-HBe sun changes 7 examples, and positive rate of rotation is 25.93%, cloudy 1 example of changeing of anti-HBc, negative conversion rate is 2.7%, does not have 1 example and knock-on occurs.
3 conclusions
In order further to prove this medicine reliability and effective degree, we study this medicine in strict accordance with the clinical medicine design, last 15 months, found that soothing liver-QI removing food stagnancy pill for curing hepatitis B clinical cure rate is 30.03%, produce effects 36.63%, take a turn for the better 26.07%, invalid 7.26%, total effective rate reaches 92.74%.And type and liver-depression and spleen-insufficiency type curative effect are not better to the greatest extent to hepatitis B traditional Chinese medical science typing damp and hot to find soothing liver-QI removing food stagnancy ball, and type of deficiency of both QI and YIN and qi stagnation and blood stasis type then take second place, and soothing liver-QI YIN-deficiency type and yang deficiency of spleen and stomache more take second place.Better to the chronic liver effect of moving in the doctor trained in Western medicine typing, and to chronic active hepatitis, liver cirrhosis due to hbv and hepatitis B virus carriers then take second place.
This research still points out soothing liver-QI removing food stagnancy ball to improving clinical symptoms, and sign and laboratory examination abnormal index all have better action to normal conversion.
Research finds that also soothing liver-QI removing food stagnancy ball has better action to the conversion of HBsAg, the anti-HBe of HBeAg, wherein the HBsAg negative conversion rate is 15.59%, the HBeAg negative conversion rate is 45.12%, and it is 42.35% that anti-HBe changes positive rate, and this shows that soothing liver-QI removing food stagnancy ball has the obvious suppression effect to hepatitis B replication.
In the relative analysis of using soothing liver-QI removing food stagnancy ball different course, find that itself and matched group per course of treatment of difference all have significance meaning (P<0.001), and its curative effect prolongs in time and improves.
This research has been carried out trimestral treatment again to 53 routine hepatitis B patients, and the tracing study result controls 40 examples, produce effects 9 examples, and effective 4 examples, total effective rate 100%, and, show that the late result of soothing liver-QI removing food stagnancy ball is better to the better action of having killed of hepatitis B virus duplication.
53 examples are followed up a case by regular visits in this research, and patient symptom disappears, and liver function is recovered fully and be stable.The HBeAg negative conversion rate is during from drug withdrawal 63.33%, and to drug withdrawal 27.27% in the time of 8 months, maintenance will continue cloudy cloudy commentaries on classics that change and continue, anti-HBe sun rate of rotation is during from drug withdrawal 32.50%, to drug withdrawal 25.93% in the time of 8 months, keeping continuing sun changes, and further having showed soothing liver-QI removing food stagnancy ball has late result preferably.
In a word, soothing liver-QI removing food stagnancy ball has therapeutical effect preferably to chronic hepatitis B, and its curative effect prolongs in time and improve, in the recent period and long-term effect all comparatively satisfied.Modern pharmacological research confirms that also this medicine not only can alleviate hepatocellular degeneration, necrosis, and effects such as the good jaundice that disappears, function of gallbladder promoting are arranged, and also significant to preventing cirrhotic generation, may be a kind of good immunomodulator.Therefore, chronic hepatitis B patient can select for use soothing liver-QI removing food stagnancy ball to treat clinically.In this medicine clinical research process, according to each medical institutions provide objective data, treat for many years in conjunction with the clinician that hepatopathy is known from experience and patient's reflection, we think that " soothing liver-QI removing food stagnancy ball " take safety, curative effect is reliable, does not find untoward reaction, and clinical effectiveness is better than other same veriety.
The specific embodiment
Embodiment 1
Take by weighing by following proportioning:
Herba Artemisiae Scopariae 235g Radix Bupleuri 277g Radix Angelicae Sinensis 39g Radix Paeoniae Alba 115g
Radix Salviae Miltiorrhizae 475g Radix Curcumae 39g Rhizoma Corydalis 277g rhizoma sparganic 39g
Rhizoma Curcumae 39g Rhizoma Cyperi 277g Fructus Toosendan 39g Radix Codonopsis 396g
Rhizoma Atractylodis Macrocephalae 39g Radix Astragali 712g Poria 475g Fructus Aurantii Immaturus 39g
Fructus Amomi 39g Semen Arecae 113g Lignum Aquilariae Resinatum 19g Radix Glycyrrhizae 277g
Medicine of the present invention can obtain big honeyed pills by following method:
1. get Radix Bupleuri, Rhizoma Corydalis, Rhizoma Curcumae, Rhizoma Cyperi and carry out processed according to the vinegar system method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get rhizoma sparganic and carry out processed according to the concocting method of regulation under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get the Radix Paeoniae Alba, Fructus Toosendan according to this kind item of Chinese Pharmacopoeia (2005 editions an one) down the concocting method of regulation carry out processed;
Get the Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus carries out processed according to the parched with bran method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get Radix Codonopsis, the Radix Astragali, Radix Glycyrrhizae and carry out processed according to the processed with honey method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one).
2. get Herba Artemisiae Scopariae, Radix Bupleuri (vinegar system), Radix Angelicae Sinensis, the Radix Paeoniae Alba (stir-fry), Radix Salviae Miltiorrhizae, Radix Curcumae, Rhizoma Corydalis (vinegar system), rhizoma sparganic (system), Rhizoma Curcumae (vinegar system), Rhizoma Cyperi (vinegar system), Fructus Toosendan (stir-fry), Radix Codonopsis (processed with honey), the Rhizoma Atractylodis Macrocephalae (parched with bran), the Radix Astragali (processed with honey), Poria, Fructus Aurantii Immaturus (parched with bran), Fructus Amomi, Semen Arecae, Lignum Aquilariae Resinatum, Radix Glycyrrhizae (processed with honey) 20 flavors, be ground into fine powder, sieve mixing.
3. get above-mentioned fine powder, every 100g adds refined honey 130g~150g, makes big honeyed pills.
Embodiment 2
Take by weighing by following proportioning:
Herba Artemisiae Scopariae 450g Radix Bupleuri 135g Radix Angelicae Sinensis 135g Radix Paeoniae Alba 300g
Radix Salviae Miltiorrhizae 300g Radix Curcumae 225g Rhizoma Corydalis 135g rhizoma sparganic 135g
Rhizoma Curcumae 135g Rhizoma Cyperi 135g Fructus Toosendan 135g Radix Codonopsis 225g
Rhizoma Atractylodis Macrocephalae 135g Radix Astragali 450g Poria 300g Fructus Aurantii Immaturus 135g
Fructus Amomi 135g Semen Arecae 135g Lignum Aquilariae Resinatum 90g Radix Glycyrrhizae 135g
Production method: with embodiment 1 production method.
Embodiment 3
Take by weighing by following proportioning:
Herba Artemisiae Scopariae 290g Radix Bupleuri 39g Radix Angelicae Sinensis 277g Radix Paeoniae Alba 200g
Radix Salviae Miltiorrhizae 115g Radix Curcumae 396g Rhizoma Corydalis 39g rhizoma sparganic 277g
Rhizoma Curcumae 277g Rhizoma Cyperi 39g Fructus Toosendan 277g Radix Codonopsis 39g
Rhizoma Atractylodis Macrocephalae 277g Radix Astragali 235g Poria 115g Fructus Aurantii Immaturus 277g
Fructus Amomi 277g Semen Arecae 277g Lignum Aquilariae Resinatum 198g Radix Glycyrrhizae 39g
Production method: with embodiment 1 production method.
Embodiment 4
Take by weighing by following proportioning:
Herba Artemisiae Scopariae 712g Radix Bupleuri 100g Radix Angelicae Sinensis 100g Radix Paeoniae Alba 475g
Radix Salviae Miltiorrhizae 200g Radix Curcumae 200g Rhizoma Corydalis 100g rhizoma sparganic 135g
Rhizoma Curcumae 135g Rhizoma Cyperi 170g Fructus Toosendan 100g Radix Codonopsis 260g
Rhizoma Atractylodis Macrocephalae 100g Radix Astragali 533g Poria 150g Fructus Aurantii Immaturus 100g
Fructus Amomi 100g Semen Arecae 39g Lignum Aquilariae Resinatum 151g Radix Glycyrrhizae 100g
Production method: with embodiment 1 production method.
Embodiment 5
Take by weighing by following proportioning:
Herba Artemisiae Scopariae 450g Radix Bupleuri 135g Radix Angelicae Sinensis 135g Radix Paeoniae Alba 300g
Radix Salviae Miltiorrhizae 300g Radix Curcumae 225g Rhizoma Corydalis 135g rhizoma sparganic 135g
Rhizoma Curcumae 135g Rhizoma Cyperi 135g Fructus Toosendan 135g Radix Codonopsis 225g
Rhizoma Atractylodis Macrocephalae 135g Radix Astragali 450g Poria 300g Fructus Aurantii Immaturus 135g
Fructus Amomi 135g Semen Arecae 135g Lignum Aquilariae Resinatum 90g Radix Glycyrrhizae 135g
Medicine of the present invention can obtain water-honeyed pill by following method:
1. get Radix Bupleuri, Rhizoma Corydalis, Rhizoma Curcumae, Rhizoma Cyperi and carry out processed according to the vinegar system method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get rhizoma sparganic and carry out processed according to the concocting method of regulation under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get the Radix Paeoniae Alba, Fructus Toosendan according to this kind item of Chinese Pharmacopoeia (2005 editions an one) down the concocting method of regulation carry out processed;
Get the Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus carries out processed according to the parched with bran method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get Radix Codonopsis, the Radix Astragali, Radix Glycyrrhizae and carry out processed according to the processed with honey method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one).
2. get Herba Artemisiae Scopariae, Radix Bupleuri (vinegar system), Radix Angelicae Sinensis, the Radix Paeoniae Alba (stir-fry), Radix Salviae Miltiorrhizae, Radix Curcumae, Rhizoma Corydalis (vinegar system), rhizoma sparganic (system), Rhizoma Curcumae (vinegar system), Rhizoma Cyperi (vinegar system), Fructus Toosendan (stir-fry), Radix Codonopsis (processed with honey), the Rhizoma Atractylodis Macrocephalae (parched with bran), the Radix Astragali (processed with honey), Poria, Fructus Aurantii Immaturus (parched with bran), Fructus Amomi, Semen Arecae, Lignum Aquilariae Resinatum, Radix Glycyrrhizae (processed with honey) 20 flavors, be ground into fine powder, sieve mixing.
3. get above-mentioned fine powder, every 100g adds about 15ml water with refined honey 10g~15g, and mixing is made water-honeyed pill.
4. get above-mentioned wet ball, drying, coating, polishing, packing gets finished product.
Embodiment 6
Take by weighing by following proportioning:
Herba Artemisiae Scopariae 90g Radix Bupleuri 27g Radix Angelicae Sinensis 27g Radix Paeoniae Alba 60g
Radix Salviae Miltiorrhizae 60g Radix Curcumae 45g Rhizoma Corydalis 27g rhizoma sparganic 27g
Rhizoma Curcumae 27g Rhizoma Cyperi 27g Fructus Toosendan 27g Radix Codonopsis 45g
Rhizoma Atractylodis Macrocephalae 27g Radix Astragali 90g Poria 60g Fructus Aurantii Immaturus 27g
Fructus Amomi 27g Semen Arecae 27g Lignum Aquilariae Resinatum 18g Radix Glycyrrhizae 27g
Medicine of the present invention can obtain tablet by following method:
1. get Radix Angelicae Sinensis, Semen Arecae, Lignum Aquilariae Resinatum, mixing, the system fine powder, standby.
2. get Radix Bupleuri, Rhizoma Corydalis, Rhizoma Curcumae, Rhizoma Cyperi and carry out processed according to the vinegar system method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get rhizoma sparganic and carry out processed according to the concocting method of regulation under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get the Radix Paeoniae Alba, Fructus Toosendan according to this kind item of Chinese Pharmacopoeia (2005 editions an one) down the concocting method of regulation carry out processed;
Get the Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus carries out processed according to the parched with bran method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get Radix Codonopsis, the Radix Astragali, Radix Glycyrrhizae and carry out processed according to the processed with honey method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one).
3. get Herba Artemisiae Scopariae, Radix Bupleuri (vinegar system), the Radix Paeoniae Alba (stir-fry), Radix Salviae Miltiorrhizae, Radix Curcumae, Rhizoma Corydalis (vinegar system), rhizoma sparganic (system), Rhizoma Curcumae (vinegar system), Rhizoma Cyperi (vinegar system), Fructus Toosendan (stir-fry), Radix Codonopsis (processed with honey), the Rhizoma Atractylodis Macrocephalae (parched with bran), the Radix Astragali (processed with honey), Poria, Fructus Aurantii Immaturus (parched with bran), Fructus Amomi, Radix Glycyrrhizae (processed with honey) 17 flavors, decoct with water twice, for the first time add 8 times of amounts of water, decocted 2 hours; For the second time add 6 times of amounts of water, decocted 1 hour, merge decocting liquid, filter, filtrate decompression is concentrated into the thick paste that relative density is 1.30 (20 ℃), drying, and the system fine powder, standby.
4. get above-mentioned two kinds of fine powders, add soluble starch 22g, mixing with 80% ethanol 200ml moistening, is granulated, and is lower than 60 ℃ of dryings.
5. get dried particles, add carboxymethyl starch sodium 15g, magnesium stearate 1g, mixing is pressed into 1000, sugar coating or film-coat, promptly.
Embodiment 7
Take by weighing by following proportioning:
With embodiment 6 proportionings.
Medicine of the present invention can obtain capsule by following method:
1. with 3 steps operation before embodiment 6 production methods.
2. get above-mentioned two kinds of fine powders, add dextrin 48g, mixing with 80% ethanol 200ml moistening, is granulated, and is lower than 60 ℃ of dryings.
3. get dried particles, load capsule, make 1000, promptly.
Embodiment 8
Take by weighing by following proportioning:
With embodiment 6 proportionings.
Medicine of the present invention can obtain mixture by following method:
1. get Radix Bupleuri, Rhizoma Corydalis, Rhizoma Curcumae, Rhizoma Cyperi and carry out processed according to the vinegar system method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get rhizoma sparganic and carry out processed according to the concocting method of regulation under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get the Radix Paeoniae Alba, Fructus Toosendan according to this kind item of Chinese Pharmacopoeia (2005 editions an one) down the concocting method of regulation carry out processed;
Get the Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus carries out processed according to the parched with bran method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get Radix Codonopsis, the Radix Astragali, Radix Glycyrrhizae and carry out processed according to the processed with honey method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one).
2. get Herba Artemisiae Scopariae, Radix Bupleuri (vinegar system), Radix Angelicae Sinensis, the Radix Paeoniae Alba (stir-fry), Radix Salviae Miltiorrhizae, Radix Curcumae, Rhizoma Corydalis (vinegar system), rhizoma sparganic (system), Rhizoma Curcumae (vinegar system), Rhizoma Cyperi (vinegar system), Fructus Toosendan (stir-fry), Radix Codonopsis (processed with honey), the Rhizoma Atractylodis Macrocephalae (parched with bran), the Radix Astragali (processed with honey), Poria, Fructus Aurantii Immaturus (parched with bran), Fructus Amomi, Semen Arecae, Lignum Aquilariae Resinatum, Radix Glycyrrhizae (processed with honey) 20 flavors, decoct with water twice, for the first time add 8 times of amounts of water, decocted 2 hours; For the second time add 6 times of amounts of water, decocted 1 hour, merge medicinal liquid, being evaporated to coherent density is the clear paste of 1.10 (20 ℃).
3. get above-mentioned clear paste, left standstill 24 hours, filter, being evaporated to coherent density is the clear paste of 1.12 (20 ℃), and standing over night filters, and adds water to 2200ml, stir evenly, and embedding, sterilization promptly gets mixture.
Embodiment 9
Take by weighing by following proportioning:
With embodiment 6 proportionings.
Medicine of the present invention can obtain granule by following method:
1. get Radix Bupleuri, Rhizoma Corydalis, Rhizoma Curcumae, Rhizoma Cyperi and carry out processed according to the vinegar system method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get rhizoma sparganic and carry out processed according to the concocting method of regulation under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get the Radix Paeoniae Alba, Fructus Toosendan according to this kind item of Chinese Pharmacopoeia (2005 editions an one) down the concocting method of regulation carry out processed;
Get the Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus carries out processed according to the parched with bran method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one);
Get Radix Codonopsis, the Radix Astragali, Radix Glycyrrhizae and carry out processed according to the processed with honey method in the concocting method under this kind item of Chinese Pharmacopoeia (2005 editions an one).
2. get Herba Artemisiae Scopariae, Radix Bupleuri (vinegar system), Radix Angelicae Sinensis, the Radix Paeoniae Alba (stir-fry), Radix Salviae Miltiorrhizae, Radix Curcumae, Rhizoma Corydalis (vinegar system), rhizoma sparganic (system), Rhizoma Curcumae (vinegar system), Rhizoma Cyperi (vinegar system), Fructus Toosendan (stir-fry), Radix Codonopsis (processed with honey), the Rhizoma Atractylodis Macrocephalae (parched with bran), the Radix Astragali (processed with honey), Poria, Fructus Aurantii Immaturus (parched with bran), Fructus Amomi, Semen Arecae, Lignum Aquilariae Resinatum, Radix Glycyrrhizae (processed with honey) 20 flavors, decoct with water twice, for the first time add 8 times of amounts of water, decocted 2 hours; For the second time add 6 times of amounts of water, decocted 1 hour, merge medicinal liquid, being evaporated to coherent density is the thick paste of 1.30 (20 ℃).
3. get above-mentioned thick paste, add dextrin 242g, mixing is granulated, and is lower than 60 ℃ of dryings.
4. get dried particles, adorn 220 bags, promptly.
Claims (5)
1. a medicine that is used for the treatment of chronic hepatitis B is characterized in that it is the medicament of being made by following weight percentages: Herba Artemisiae Scopariae 6~18%, Radix Bupleuri 1~7%, Radix Angelicae Sinensis 1~7%, the Radix Paeoniae Alba 3~12%, Radix Salviae Miltiorrhizae 3~12%, Radix Curcumae 1~10%, Rhizoma Corydalis 1~7%, rhizoma sparganic 1~7%, Rhizoma Curcumae 1~7%, Rhizoma Cyperi 1~7%, Fructus Toosendan 1~7%, Radix Codonopsis 1~10%, the Rhizoma Atractylodis Macrocephalae 1~7%, the Radix Astragali 6~18%, Poria 3~12%, Fructus Aurantii Immaturus 1~7%, Fructus Amomi 1~7%, Semen Arecae 1~7%, Lignum Aquilariae Resinatum 0.5~5%, Radix Glycyrrhizae 1~7%.
2. according to the described a kind of medicine that is used for the treatment of chronic hepatitis B of claim 1, it is characterized in that the weight proportion of described each raw material is: Herba Artemisiae Scopariae 450g, Radix Bupleuri 135g, Radix Angelicae Sinensis 135g, Radix Paeoniae Alba 300g, Radix Salviae Miltiorrhizae 300g, Radix Curcumae 225g, Rhizoma Corydalis 135g, rhizoma sparganic 135g, Rhizoma Curcumae 135g, Rhizoma Cyperi 135g, Fructus Toosendan 135g, Radix Codonopsis 225g, Rhizoma Atractylodis Macrocephalae 135g, Radix Astragali 450g, Poria 300g, Fructus Aurantii Immaturus 135g, Fructus Amomi 135g, Semen Arecae 135g, Lignum Aquilariae Resinatum 90g, Radix Glycyrrhizae 135g.
3. according to claim 1 or 2 described a kind of medicines that are used for the treatment of chronic hepatitis B, it is characterized in that described Radix Bupleuri, Rhizoma Corydalis, Rhizoma Curcumae, Rhizoma Cyperi according to 2005 editions one one of Chinese Pharmacopoeia, the vinegar system method under this kind item in the concocting method is carried out processed; Rhizoma sparganic is according to 2005 editions one one of Chinese Pharmacopoeia, and this kind item concocting method of regulation down carries out processed; The Radix Paeoniae Alba, Fructus Toosendan are according to 2005 editions one one of Chinese Pharmacopoeia, and this kind item concocting method of regulation down carries out processed; The Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus are according to 2005 editions one one of Chinese Pharmacopoeia, and the parched with bran method under this kind item in the concocting method is carried out processed; Radix Codonopsis, the Radix Astragali, Radix Glycyrrhizae are according to 2005 editions one one of Chinese Pharmacopoeia, and the processed with honey method under this kind item in the concocting method is carried out processed.
4. according to claim 1 or 2 described a kind of medicines that are used for the treatment of chronic hepatitis B, it is characterized in that described medicament is the above a routine dosage form for oral administration of pharmaceutics.
5. according to the described a kind of medicine that is used for the treatment of chronic hepatitis B of claim 4, it is characterized in that described medicament is big honeyed pills agent, water-honeyed pill, tablet, capsule, mixture, granule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101508970A CN101357219B (en) | 2008-09-04 | 2008-09-04 | Medicine for treating chronic hepatitis B |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101508970A CN101357219B (en) | 2008-09-04 | 2008-09-04 | Medicine for treating chronic hepatitis B |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101357219A CN101357219A (en) | 2009-02-04 |
CN101357219B true CN101357219B (en) | 2011-06-15 |
Family
ID=40329905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101508970A Active CN101357219B (en) | 2008-09-04 | 2008-09-04 | Medicine for treating chronic hepatitis B |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101357219B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102166329B (en) * | 2010-03-17 | 2012-08-22 | 慕少英 | Medicine for treating leukopenia caused by chronic hepatitis B or interferon and preparation method thereof |
CN101979070B (en) * | 2010-10-27 | 2011-12-28 | 苏桂华 | Chinese medicament for treating hepatitis B |
CN102727633B (en) * | 2012-07-20 | 2014-03-19 | 成都中医药大学 | Pharmaceutical composition for treating chronic hepatitis B and preparation method and application thereof |
CN103071114A (en) * | 2013-01-09 | 2013-05-01 | 李世柱 | Traditional Chinese medicine for curing initial-stage symptoms of liver disease |
CN104547852B (en) * | 2014-09-26 | 2018-03-06 | 董向坤 | A kind of pharmaceutical composition for treating hepatopathy |
CN104606625A (en) * | 2015-03-07 | 2015-05-13 | 徐金鹏 | Traditional Chinese medicine pill for treating hepatitis B |
CN105456517A (en) * | 2015-12-15 | 2016-04-06 | 彭国能 | A traditional Chinese medicine composition, preparation and preparation method for treating chronic hepatitis B |
CN106267082A (en) * | 2016-08-31 | 2017-01-04 | 单晓春 | Nourishing the liver acesodyne capsule and its preparation method and application |
CN106334158A (en) * | 2016-10-17 | 2017-01-18 | 亳州学院 | Traditional Chinese medicine composition for treating virus hepatitis and preparation method thereof and application |
CN106924669A (en) * | 2017-04-06 | 2017-07-07 | 吴忠市仁爱医院有限公司 | A kind of Chinese medicine composition for treating acute, chronic hepatitis |
CN108721569A (en) * | 2018-07-26 | 2018-11-02 | 李茂辉 | A kind of drug and preparation method thereof for treating hepatic sclerosis |
CN113456728A (en) * | 2021-08-02 | 2021-10-01 | 陈怀林 | A Chinese medicinal oral liquid for treating chronic hepatitis B, and its preparation method |
CN113559218A (en) * | 2021-08-27 | 2021-10-29 | 首都医科大学附属北京佑安医院 | A kind of traditional Chinese medicine composition for treating chronic hepatitis and its application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1943761A (en) * | 2006-10-23 | 2007-04-11 | 龙敦成 | A Medicine for treatment of ascites due to cirrhosis |
-
2008
- 2008-09-04 CN CN2008101508970A patent/CN101357219B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1943761A (en) * | 2006-10-23 | 2007-04-11 | 龙敦成 | A Medicine for treatment of ascites due to cirrhosis |
Also Published As
Publication number | Publication date |
---|---|
CN101357219A (en) | 2009-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101357219B (en) | Medicine for treating chronic hepatitis B | |
MXPA03003446A (en) | Novel medicinal herbal composition for treating liver diseases and hiv. | |
CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
CN103301267B (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
Li | Chinese herbal medicine | |
CN103599495A (en) | Chinese medicinal composition for treatment of hepatitis B | |
CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
CN105412410A (en) | Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy | |
CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
CN102671056B (en) | Chinese medicinal composition for treating hepatitis and preparation method thereof | |
CN102772747B (en) | Traditional Chinese medicine preparation for treating heat-toxicity heart-disoperation type viral myocarditis | |
CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
CN114699498A (en) | Pharmaceutical composition for resisting chronic hepatitis B and application thereof | |
CN103169838B (en) | Medicine for treating hepatitis B | |
CN106309758A (en) | Pharmaceutical composition with efficacy of resisting gastrointestinal cancer | |
CN100363034C (en) | Chinese medicinal composition for treating ascites due to cirrhosis | |
CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
CN103933386A (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications | |
CN102772665B (en) | Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |